DMK Pharmaceuticals (DMK) Stock Price, News & Analysis

Company Overview

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.04 to $0.58
• 52-Week Range: N/A
• Volume: 24.16 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $2.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Buy

DMK Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of DMK Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DMK Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Sangamo Therapeutics (SGMO) and Bakkt (BKKT).

Company Calendar

• Today: 11/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DMK
• CUSIP: N/A
• CIK: 887247
• Web: www.dmkpharmaceuticals.com
• Phone: 858-997-2400
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.50
• High Stock Price Target: $1.50
• Low Stock Price Target: $1.50
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-26,480,000.00
• Net Margins: -630.85%
• Pretax Margin: -600.29%
• Return on Equity: N/A
• Return on Assets: -251.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.58
• Quick Ratio: 0.54

Sales & Book Value

• Annual Sales: $3.62 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.38) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 10,102,000
• Free Float: 9,506,000
• Market Cap: $2.34 million
• Optionable: No Data
• Beta: 1.11